Viridian (VRDN): Two-Step Rebound Trade - FDA Catalyst Then Pipeline Re-rating
Viridian has been punished for mixed Phase 3 readouts, but the market may be over-discounting the company's IGF-1R franchise and downstream FcRn assets. With an upcoming FDA decision for veligrotug on 06/30/2026 and a capital base that supports near-term execution, VRDN offers asymmetric upside versus clearly definable downside.